These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11151088)

  • 21. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis.
    McIlleron H; Ren Y; Nuttall J; Fairlie L; Rabie H; Cotton M; Eley B; Meyers T; Smith PJ; Merry C; Maartens G
    Antivir Ther; 2011; 16(3):417-21. PubMed ID: 21555825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis coinfection and LPV/RTV.
    Carter M
    IAPAC Mon; 2004 Oct; 10(10):398. PubMed ID: 15801120
    [No Abstract]   [Full Text] [Related]  

  • 23. Plasma and cerebrospinal pharmacokinetics and pharmacodynamics in subjects taking lopinavir/ritonavir.
    Martin TM; Morse GD; Kurpewski J; Difrancesco R; Caliendo AM; Flanigan TP; Tashima KT
    AIDS; 2006 Apr; 20(7):1085-7. PubMed ID: 16603871
    [No Abstract]   [Full Text] [Related]  

  • 24. Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.
    Bongiovanni M; Chiesa E; Monforte Ad; Bini T
    Dermatol Online J; 2003 Dec; 9(5):28. PubMed ID: 14996401
    [No Abstract]   [Full Text] [Related]  

  • 25. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients.
    McCance-Katz EF; Rainey PM; Friedland G; Jatlow P
    Clin Infect Dis; 2003 Aug; 37(4):476-82. PubMed ID: 12905130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.
    Barragan P; Podzamczer D
    Expert Opin Pharmacother; 2008 Sep; 9(13):2363-75. PubMed ID: 18710360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New treatment options for HIV-infected patients].
    Wehr A
    Dtsch Med Wochenschr; 2004 May; 129(19):1093. PubMed ID: 15174468
    [No Abstract]   [Full Text] [Related]  

  • 28. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
    Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
    Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
    J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil.
    Vergara TR; Estrela RC; Suarez-Kurtz G; Schechter M; Cerbino-Neto J; Barroso PF
    Ther Drug Monit; 2006 Apr; 28(2):175-9. PubMed ID: 16628127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug interactions. Kaletra and atazanavir.
    TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919
    [No Abstract]   [Full Text] [Related]  

  • 33. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.
    Sáez-Llorens X; Violari A; Deetz CO; Rode RA; Gomez P; Handelsman E; Pelton S; Ramilo O; Cahn P; Chadwick E; Allen U; Arpadi S; Castrejón MM; Heuser RS; Kempf DJ; Bertz RJ; Hsu AF; Bernstein B; Renz CL; Sun E
    Pediatr Infect Dis J; 2003 Mar; 22(3):216-24. PubMed ID: 12634581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).
    Yeni P; Lamarca A; Berger D; Cimoch P; Lazzarin A; Salvato P; Smaill FM; Teofilo E; Madison SJ; Nichols WG; Adkison KK; Bonny T; Millard J; McCarty D;
    HIV Med; 2009 Feb; 10(2):116-24. PubMed ID: 19200175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-HIV agents. Monotherapy studies--points to consider.
    TreatmentUpdate; 2008 Jan; 20(1):3-4. PubMed ID: 18320692
    [No Abstract]   [Full Text] [Related]  

  • 37. [No resistance even after 1 year. New drug combination against HIV].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():108. PubMed ID: 11373766
    [No Abstract]   [Full Text] [Related]  

  • 38. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
    J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.
    Bates DE; Herman RJ
    Ann Pharmacother; 2006 Jun; 40(6):1190-5. PubMed ID: 16720703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Kaletra (lopinavir/ritonavir--a new HIV protease inhibitor].
    Ershov FI; Kas'ianova NV; Vasil'ev AN
    Antibiot Khimioter; 2002; 47(11):27-9. PubMed ID: 12698577
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.